Volume 14, Number 3—March 2008
Research
Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel
Table 2
Parameter | Patients included in the current study (n = 186) | Patients tested for NTM (n = 265) | Patients not tested for NTM (n = 203) | p value |
---|---|---|---|---|
Age (mean ± SD) | 20.51 ± 10.40 | 20.22 ± 10.53 | 13.99 ± 10.70 | 0.0001 |
Sex, F/M | 74/112 | 105/160 | 86/117 | 0.54 |
Hemoptysis | 22 | 23 | 4 | 0.002 |
FEV1, L/s (mean ± SD) | 67.90 ± 22.09 | 65.18 ± 21.69 | 82.94 ± 16.20 | 0.0001 |
Pancreatic insufficiency | 135 | 151 | 131 | 0.09 |
Hospitalization, d (mean ± SD) | 21.77 ± 28.54 | 23.80 ± 32.44 | 8.44 ± 14.03 | 0.0001 |
Administration of antimicrobial agents, d (mean ± SD) | 22.66 ± 47.51 | 19.98 ± 45.52 | 2.30 ± 10.28 | 0.0001 |
Azithromycin | 104 | 114 | 51 | 0.001 |
Ibuprofen | 7 | 15 | 6 | 0.16 |
Insulin | 17 | 20 | 9 | 0.16 |
Systemic steroids | 13 | 37 | 19 | 0.12 |
Inhaled steroids | 96 | 106 | 105 | 0.01 |
*NTM, nontuberculous mycobacteria; SD, standard deviation; FEV1, forced expiratory volume in 1 s.
1These authors contributed equally to this work.
2Current affiliation: Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.